[go: up one dir, main page]

WO2015003581A1 - Polypeptide bivalent inhibant une infection au vih - Google Patents

Polypeptide bivalent inhibant une infection au vih Download PDF

Info

Publication number
WO2015003581A1
WO2015003581A1 PCT/CN2014/081616 CN2014081616W WO2015003581A1 WO 2015003581 A1 WO2015003581 A1 WO 2015003581A1 CN 2014081616 W CN2014081616 W CN 2014081616W WO 2015003581 A1 WO2015003581 A1 WO 2015003581A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
formula
polypeptide
aca
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2014/081616
Other languages
English (en)
Chinese (zh)
Inventor
刘克良
凌彦博
姜喜凤
薛慧芳
王昆
蔡利锋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Publication of WO2015003581A1 publication Critical patent/WO2015003581A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention belongs to the field of biomedicine and relates to a polypeptide against HIV infection. Specifically, the present invention relates to a bivalent polypeptide represented by Formula I or Formula II, a derivative thereof, a stereoisomer thereof, or no physiological toxicity thereof. Salt.
  • the invention further relates to a pharmaceutical composition comprising a bivalent polypeptide of formula I or formula II, a derivative thereof, a stereoisomer thereof, or a salt thereof which is not physiologically toxic, and a bivalent polypeptide of formula I or formula Use of a derivative thereof, a stereoisomer thereof, or a physiologically toxic salt thereof for the preparation of a medicament for treating or preventing a disease associated with HIV infection, particularly Acquired Immune Deficiency Syndrome (AIDS) .
  • AIDS Acquired Immune Deficiency Syndrome
  • HIV Human Immunodeficiency Virus
  • HIV-1 HIV-1
  • HIV-2 HIV-1 is one of the more popular ones.
  • Env The infection of human host cells by HIV-1 virus requires a process of fusion of the viral membrane with the target cell membrane. Such a process needs to be enveloped by a viral glycoprotein (Env).
  • Env consists of two parts, a surface subunit gpl20 that binds to the host cell, and a transmembrane subunit gp41 that binds to the host to mediate membrane fusion.
  • Gp41 is inserted into a host cell through its amino-terminal fusion peptide to promote the fusion process of the viral membrane with the target cell membrane.
  • the completion of the fusion state requires the viral gp41 N-terminal repeat (N-HR) and C-terminal repeat (C-HR) folding A six-helix bundle (6-HB) is formed.
  • Inhibitors of the glycoprotein gp41 acting on the HIV-1 virus surface are also known as fusion inhibitors, of which T-20 is currently the only polypeptide-based HIV fusion inhibitor for clinical use.
  • the peptide or small molecule fusion inhibitor of this fusion link competitively binds to the gp41 target exposed in the process to inhibit the formation of the virus itself 6-HB, thereby inhibiting the virus from invading the human immune cells.
  • the trivalent HIV inhibitor designed by Hirokazu et al., with a C34-based sequence, has a cell fusion IC 5Q value of 1.3 nm, which is about 34-fold more active than the starting sequence (W. Nomura, C Hashimoto, A. Ohya, K. Miyauchi, E. Urano, T. Tanaka, T. Narumi, T. Nakahara, J. a. Komano, N. Yamamoto, H. Tamamura, ChemMedChem 2012, 7, 205-208. ). Summary of the invention
  • the object of the present invention is to find a bivalent anti-HIV substance having a relatively high biological activity starting from a shorter sequence.
  • the bivalent polypeptide of the formula I or formula, or a derivative thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof has good activity for inhibiting target cells infected with HIV, and thus can be used as a medicament for treating or preventing HIV. Infection, thus completing the present invention.
  • a first aspect of the invention relates to a bivalent polypeptide, derivative, stereoisomer or pharmaceutically acceptable salt thereof, of formula I or formula II: among them
  • C is L-form or D-type cysteine
  • Z is a polypeptide sequence of L-form or D-form
  • a disulfide bond is used between the two monovalent polypeptide chains.
  • the composition of the non-natural amino acid is selected from the group consisting of ⁇ -alanine (BAla), 6-aminocaproic acid (Aca), and triethylene glycol (ethylene group having one end amino group and one end carboxyl group).
  • BAla ⁇ -alanine
  • Aca 6-aminocaproic acid
  • triethylene glycol ethylene group having one end amino group and one end carboxyl group.
  • Teg NH 2 -CH 2 CH 2 -0-CH 2 CH 2 -0-CH 2 CH 2 -0-CH 2 CH 2 -0-CH 2 CH 2 -COOH.
  • Z is selected from the group consisting of:
  • the bivalent polypeptide of Formula I or Formula II is selected from the group consisting of:
  • a disulfide bond is used between the two monovalent polypeptide chains.
  • the natural amino acid includes alanine (Ala), cineine (Val), leuco acid (Leu), isoleucine (ne), proline (Pro), phenylalanine. (Phe), tryptophan (Trp), melitic acid (Met), saccharate (Gly), serine (ser), threonine (Thr), half; acid (Cys), tyrosine (Tyr ), Asn, Gin, Lys, Arginine (Arg), Histidine (His), Aspartic Acid (Asp), Acid (Glu).
  • the GGSTeg means glycine glycine threonine plus Teg.
  • the above compound number [(1) ⁇ (22)] represents the compound (bivalent polypeptide).
  • Another aspect of the invention relates to a pharmaceutical composition comprising at least one bivalent polypeptide of the formula I or formula ⁇ of any one of the first aspects of the invention, a derivative thereof, a stereoisomer, or a pharmaceutically acceptable An acceptable salt, and, optionally, a pharmaceutically acceptable carrier or excipient.
  • a further aspect of the invention relates to a bivalent polypeptide, derivative, stereoisomer, or pharmaceutically acceptable salt thereof of Formula I or Formula ⁇ of any one of the first aspects of the invention for the preparation of an HIV fusion inhibitor Use in.
  • a further aspect of the invention relates to an HIV fusion inhibitor comprising at least one A divalent polypeptide, derivative, stereoisomer, or pharmaceutically acceptable salt thereof of Formula I or Formula II according to any one of the first aspects of the invention.
  • a further aspect of the invention relates to a bivalent polypeptide, derivative, stereoisomer, or pharmaceutically acceptable salt thereof of Formula I or Formula ⁇ of any one of the first aspects of the invention, for use in the preparation of a therapeutic or Use in the prevention of HIV-related diseases, especially AIDS drugs.
  • Still another aspect of the present invention relates to a method of treating or preventing a disease associated with HIV infection, particularly AIDS, the method comprising administering to a subject receiving treatment or prevention an effective amount of Formula I or Formula 1 of any one of the first aspects of the present invention.
  • the HIV means HIV-1 or HIV-2, preferably HIV-1.
  • the monovalent polypeptide and the monomer of the bivalent polypeptide have the same meaning, meaning
  • the disulfide bond means -S - S -.
  • the (C-LrZ refers to 0 -L factory Z , where ⁇
  • the present inventors synthesized a bivalent polypeptide by a certain method, and a disulfide bond was used between two polypeptide chains of a bivalent molecule to synergistically act on two polypeptide sequences to enhance the target. Inhibition of activity, design of highly active HIV fusion inhibitors, explored new ideas for inhibiting HIV infection. detailed description
  • Env envelope glycoprotein
  • HIV Human Immunodeficiency Virus 1 human immunodeficiency virus
  • HIV-1 human immunodeficiency virus type I HIV-1 human immunodeficiency virus type I
  • TFA trifluoroacetic acid
  • Threonine Trp Tryptophan
  • the solid phase synthetic carrier used in the examples Rink-amide resin is the product of Tianjin Nankai Synthetic Co., Ltd.; HBTU, HOBT, DIEA and Fmoc protected natural acid based acid are products of Shanghai Jill Biochemical Co., Ltd. and Chengdu Chengnuo New Technology Co., Ltd. Trifluoroacetic acid (TFA), DMF, DCM are products of Beijing Bomaijie Technology Co., Ltd.; Chromatography Pure acetonitrile is Fisher's product. Other reagents are domestically produced pure products if they are not described.
  • Peptide synthesis using standard Fmoc solid phase methods Rink-Amide resin was selected and the peptide chain was extended from the C-terminus to the N-terminus.
  • the condensing agent is HBTU/HOBt/DIEA.
  • the deprotecting agent is a piperidine/DMF solution.
  • the cleavage agent is trifluoroacetic acid (TFA), and the crude peptide is dissolved in water and stored in lyophilization. It was isolated and purified by medium pressure liquid chromatography or high pressure liquid chromatography (HPLC) with a pure peptide content of >95%.
  • Matrix-assisted laser desorption time-of-flight mass spectrometry MALDI-TOF-MS was used to determine the molecular weight of the peptide sequence.
  • Rink Amide resin 0.51g (0.233mmol) of Rink Amide resin was weighed into the CS Biol36 peptide synthesizer reactor, then amino acid, activator, activated base, deprotecting reagent, blocking reagent according to the concentration (protected amino acid: 0.25M DMF solution, Activator: 0.2MHBTU/HOBt in DMF solution, activated base: 0.4MDIEA in DMF solution, deprotecting agent: 20% v/v, piperidine in DMF solution, blocking reagent: 20% v/v, acetic acid Sf in DMF solution After the configuration, synthesis was carried out using a CS Biol36 polypeptide synthesizer.
  • peptide resin was washed with DCM for 3 times, then shrunk with anhydrous methanol, and dried under vacuum at room temperature to obtain a peptide resin of 2.11.
  • the dried polypeptide was placed in a 500 ml eggplant-shaped flask, and a lysing agent (v/v) was added in a ratio of 10 ml per gram of the resin.
  • the compounds (2) - (22) were synthesized according to the above method, and T20 and C34 were synthesized as described above.
  • a 20 ⁇ !/well cell lysate was plated onto a 96-well phosphor plate.
  • the thawed luciferaseassay buffer (Promega, Fitchburg, WI, USA) was added to the luciferaseassay substrate (Promega, Fitchburg, WI, USA) and added 40 ⁇ !/well in a 96-well phosphor plate. The luminescence was detected immediately on the microplate reader. Calculate IC 5 . value.
  • the compounds (1)-(22) are corresponding to the compound numbers in the examples and the inventions of the present invention, and T20 and C34 are control drugs.
  • the structure of C34 is
  • the structure of WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL, T20 (Fuzeon or enfuvirtide) is YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF.
  • the experimental results show that most of the compounds of the present invention can be compared with their monomers. More effectively inhibit HIV-1 mediated cell fusion,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un polypeptide divalent de formule I ou de formule II permettant de résister à une infection au VIH, et un dérivé, un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne également une composition pharmaceutique comprenant le polypeptide, ou un dérivé, un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci, et leur utilisation dans la préparation d'un médicament destiné au traitement ou à la prévention de maladies résultant d'une infection au VIH. Formule I : (C-L1-Z)2 　Formule II : (Z-L1-C)2
PCT/CN2014/081616 2013-07-08 2014-07-04 Polypeptide bivalent inhibant une infection au vih Ceased WO2015003581A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310283591.3A CN104277113B (zh) 2013-07-08 2013-07-08 抑制hiv感染的二价多肽
CN201310283591.3 2013-07-08

Publications (1)

Publication Number Publication Date
WO2015003581A1 true WO2015003581A1 (fr) 2015-01-15

Family

ID=52252504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/081616 Ceased WO2015003581A1 (fr) 2013-07-08 2014-07-04 Polypeptide bivalent inhibant une infection au vih

Country Status (2)

Country Link
CN (1) CN104277113B (fr)
WO (1) WO2015003581A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106317209B (zh) * 2015-07-02 2020-03-13 中国人民解放军军事医学科学院毒物药物研究所 共价交联的n肽抑制剂
CN110551179B (zh) * 2018-05-31 2022-03-15 中国科学院微生物研究所 一种经修饰的抗hiv多肽及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101993485A (zh) * 2009-08-20 2011-03-30 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
EP2377880A2 (fr) * 2008-08-13 2011-10-19 New York Blood Center Thérapie de combinaison d'inhibitors de fusion/entrée du VIH ciblant gp41

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377880A2 (fr) * 2008-08-13 2011-10-19 New York Blood Center Thérapie de combinaison d'inhibitors de fusion/entrée du VIH ciblant gp41
CN101993485A (zh) * 2009-08-20 2011-03-30 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAO, JUNPENG ET AL.: "Synthesis of N-Terminally Linked Protein and Peptide Dimers by Native Chemical Ligation", BIOCONJUGATE CHEMISTRY, vol. 21, 25 October 2010 (2010-10-25) *

Also Published As

Publication number Publication date
CN104277113A (zh) 2015-01-14
CN104277113B (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
CN114736272B (zh) 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
TWI341844B (en) Hiv fusion inhibitor peptides with improved biological properties
KR20050120663A (ko) 장기간 작용하는 생물학적 활동 컨쥬게이트들
CN111643656A (zh) 广谱冠状病毒膜融合抑制剂及其抗艾滋病病毒的应用
WO2009155789A1 (fr) Polypeptides et leurs dérivés inhibant l’infection par le vih
WO2019136824A1 (fr) Polypeptide inhibant une infection par mers-cov
TW200416225A (en) Pegylated T20 polypeptide
AU2023378464A1 (en) Membrane fusion inhibitor for inhibiting aids virus and drug-resistant strain thereof, and pharmaceutical use thereof
WO2015003581A1 (fr) Polypeptide bivalent inhibant une infection au vih
WO2011110049A1 (fr) Polypeptide de fusion anti-vih et son utilisation
CN109069577B (zh) Hiv进入的d-肽抑制剂以及使用方法
WO2015127862A1 (fr) Conjugué triterpène-polypeptide, composition pharmaceutique et utilisation associée
WO2012000459A1 (fr) Polypeptide anti-infection par le vih, composition et utilisation
CN103483428B (zh) 抑制hiv感染的小分子‑多肽缀合物
WO2013075606A1 (fr) Conjugué petite molécule-polypeptide inhibant une infection par le vih
CN106397548A (zh) 用于抑制hiv感染的多肽及其药物用途
CN108822190B (zh) 多肽及其药物组合物和用途
WO2022223007A1 (fr) Composé polypeptidique antiviral
WO2013075594A1 (fr) Polypeptide anti-infection par le vih conçu artificiellement, composition et utilisation associées
TW200427697A (en) Pegylated t1249 polypeptide
US20140357577A1 (en) HIV Membrane Fusion Inhibitors
CN106146624B (zh) 定点共价交联的天然n肽类的hiv-1抑制剂
WO2012139519A1 (fr) Peptide cyclique et son application médicale
CN106317209B (zh) 共价交联的n肽抑制剂
WO2011127624A1 (fr) Peptide anti-vih

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14823315

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14823315

Country of ref document: EP

Kind code of ref document: A1